Successful use of infliximab in macrophage activation syndrome with severe CNS involvement.
Sellmer
A
A
Stausbøl-Grøn
B
B
Krag-Olsen
B
B
Herlin
T
T
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D002648:Child; D016207:Cytokines / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000069285:Infliximab; D055501:Macrophage Activation Syndrome / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism; D008279:Magnetic Resonance Imaging; D008297:Male; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D016207:Cytokines; D000069285:Infliximab